611 related articles for article (PubMed ID: 22903760)
21. Deficient TSC1/TSC2-complex suppression of SOX9-osteopontin-AKT signalling cascade constrains tumour growth in tuberous sclerosis complex.
Jin F; Jiang K; Ji S; Wang L; Ni Z; Huang F; Li C; Chen R; Zhang H; Hu Z; Zha X
Hum Mol Genet; 2017 Jan; 26(2):407-419. PubMed ID: 28013293
[TBL] [Abstract][Full Text] [Related]
22. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways.
Kwiatkowski DJ; Manning BD
Hum Mol Genet; 2005 Oct; 14 Spec No. 2():R251-8. PubMed ID: 16244323
[TBL] [Abstract][Full Text] [Related]
23. Development of hypomelanotic macules is associated with constitutive activated mTORC1 in tuberous sclerosis complex.
Møller LB; Schönewolf-Greulich B; Rosengren T; Larsen LJ; Ostergaard JR; Sommerlund M; Ostenfeldt C; Stausbøl-Grøn B; Linnet KM; Gregersen PA; Jensen UB
Mol Genet Metab; 2017 Apr; 120(4):384-391. PubMed ID: 28336152
[TBL] [Abstract][Full Text] [Related]
24. Analysis of both TSC1 and TSC2 for germline mutations in 126 unrelated patients with tuberous sclerosis.
Niida Y; Lawrence-Smith N; Banwell A; Hammer E; Lewis J; Beauchamp RL; Sims K; Ramesh V; Ozelius L
Hum Mutat; 1999; 14(5):412-22. PubMed ID: 10533067
[TBL] [Abstract][Full Text] [Related]
25. Tuberous sclerosis complex regulates Drosophila neuromuscular junction growth via the TORC2/Akt pathway.
Natarajan R; Trivedi-Vyas D; Wairkar YP
Hum Mol Genet; 2013 May; 22(10):2010-23. PubMed ID: 23393158
[TBL] [Abstract][Full Text] [Related]
26. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.
Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ
J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586
[TBL] [Abstract][Full Text] [Related]
27. Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation.
Hwang SK; Lee JH; Yang JE; Lim CS; Lee JA; Lee YS; Lee K; Kaang BK
Mol Brain; 2016 May; 9(1):56. PubMed ID: 27216612
[TBL] [Abstract][Full Text] [Related]
28. Neuronal Tsc1/2 complex controls autophagy through AMPK-dependent regulation of ULK1.
Di Nardo A; Wertz MH; Kwiatkowski E; Tsai PT; Leech JD; Greene-Colozzi E; Goto J; Dilsiz P; Talos DM; Clish CB; Kwiatkowski DJ; Sahin M
Hum Mol Genet; 2014 Jul; 23(14):3865-74. PubMed ID: 24599401
[TBL] [Abstract][Full Text] [Related]
29. Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype--phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex.
Sancak O; Nellist M; Goedbloed M; Elfferich P; Wouters C; Maat-Kievit A; Zonnenberg B; Verhoef S; Halley D; van den Ouweland A
Eur J Hum Genet; 2005 Jun; 13(6):731-41. PubMed ID: 15798777
[TBL] [Abstract][Full Text] [Related]
30. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease.
Astrinidis A; Henske EP
Oncogene; 2005 Nov; 24(50):7475-81. PubMed ID: 16288294
[TBL] [Abstract][Full Text] [Related]
31. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling.
Inoki K; Li Y; Zhu T; Wu J; Guan KL
Nat Cell Biol; 2002 Sep; 4(9):648-57. PubMed ID: 12172553
[TBL] [Abstract][Full Text] [Related]
32. Mutation and polymorphism analysis of TSC1 and TSC2 genes in Indian patients with tuberous sclerosis complex.
Ali M; Girimaji SC; Markandaya M; Shukla AK; Sacchidanand S; Kumar A
Acta Neurol Scand; 2005 Jan; 111(1):54-63. PubMed ID: 15595939
[TBL] [Abstract][Full Text] [Related]
33. Biallelic TSC gene inactivation in tuberous sclerosis complex.
Crino PB; Aronica E; Baltuch G; Nathanson KL
Neurology; 2010 May; 74(21):1716-23. PubMed ID: 20498439
[TBL] [Abstract][Full Text] [Related]
34. Prolonging the survival of Tsc2 conditional knockout mice by glutamine supplementation.
Rozas NS; Redell JB; McKenna J; Moore AN; Gambello MJ; Dash PK
Biochem Biophys Res Commun; 2015 Feb; 457(4):635-9. PubMed ID: 25613864
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models.
Lee L; Sudentas P; Donohue B; Asrican K; Worku A; Walker V; Sun Y; Schmidt K; Albert MS; El-Hashemite N; Lader AS; Onda H; Zhang H; Kwiatkowski DJ; Dabora SL
Genes Chromosomes Cancer; 2005 Mar; 42(3):213-27. PubMed ID: 15578690
[TBL] [Abstract][Full Text] [Related]
36. Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling.
Gao X; Zhang Y; Arrazola P; Hino O; Kobayashi T; Yeung RS; Ru B; Pan D
Nat Cell Biol; 2002 Sep; 4(9):699-704. PubMed ID: 12172555
[TBL] [Abstract][Full Text] [Related]
37. Targeted Next Generation Sequencing reveals previously unidentified TSC1 and TSC2 mutations.
Nellist M; Brouwer RW; Kockx CE; van Veghel-Plandsoen M; Withagen-Hermans C; Prins-Bakker L; Hoogeveen-Westerveld M; Mrsic A; van den Berg MM; Koopmans AE; de Wit MC; Jansen FE; Maat-Kievit AJ; van den Ouweland A; Halley D; de Klein A; van IJcken WF
BMC Med Genet; 2015 Feb; 16():10. PubMed ID: 25927202
[TBL] [Abstract][Full Text] [Related]
38. The tuberous sclerosis complex: balancing proliferation and survival.
Tomasoni R; Mondino A
Biochem Soc Trans; 2011 Apr; 39(2):466-71. PubMed ID: 21428921
[TBL] [Abstract][Full Text] [Related]
39. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
40. Molecular and clinical analyses of 84 patients with tuberous sclerosis complex.
Hung CC; Su YN; Chien SC; Liou HH; Chen CC; Chen PC; Hsieh CJ; Chen CP; Lee WT; Lin WL; Lee CN
BMC Med Genet; 2006 Sep; 7():72. PubMed ID: 16981987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
